Beside capillary rarefaction, mechanisms leading to endothelial dysfunction and hypertension by VEGF inhibitors are related to reduced NO production, increased ET-1 release and altered renin-angiotensin system [54, 55]. Here, VEGFA is linked to hypertensive disorder.